Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience.

Nicolo' Gebbia, Conte, Giuseppina Rosaria Rita Ricciardi, Venturini, Dondi, Dario Giuffrida, Vincenzo Adamo, Colucci, Francesco Cognetti, De Placido, Masci

Risultato della ricerca: Article

8 Citazioni (Scopus)

Abstract

AIMS: Triple-negative breast cancers (TNBCs) lack expression of oestrogen, progesterone, and Human Epidermal Growth Factor 2 receptors. The NEMESI study described current Italian treatment practices in patients with operable, early-stage breast cancer (EBC).PATIENTS AND METHODS: Retrospective, observational study involving 63 Italian oncology centres. Eligible patients were aged ⩾18years with EBC (stage I-II) who had undergone surgery, received ⩾1 cycle of adjuvant chemotherapy and/or adjuvant hormonal therapy and attended an oncology centre between 1 January 2008 and 30 June 2008. This subanalysis focused on patients with TNBC. Variables evaluated included: demographic data/clinical characteristics; tumour characteristics; adjuvant therapy; compliance to chemotherapy. Continuous variables were summarised using descriptive statistics.RESULTS: Of 1894 patients in the NEMESI study, 185 patients (9.8%) had TNBC. At diagnosis, 98 patients were aged 50-70years and 114 were post-menopausal. Tumours were subcategorised as pT1mic/pT1a/pT1b/pT1c in 108 patients and pT2/pT3/pT4b in 77 patients. Mean tumour size was 2.1cm, tumours were highly undifferentiated in 144 patients and 128 patients were pNO. 179 patients received adjuvant chemotherapy; anthracyclines with or without taxanes were commonly used. 145 patients received radiotherapy.CONCLUSIONS: Adherence of Italian clinical practice to International Guidelines in the management of early-stage TNBC is satisfactory.
Lingua originaleEnglish
Numero di pagine6
RivistaDefault journal
Volumex
Stato di pubblicazionePublished - 2011

Fingerprint

Triple Negative Breast Neoplasms
Therapeutics
Adjuvant Chemotherapy
Neoplasms
Breast Neoplasms
Taxoids
Anthracyclines
Observational Studies
Progesterone

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience. / Gebbia, Nicolo'; Conte; Ricciardi, Giuseppina Rosaria Rita; Venturini; Dondi; Giuffrida, Dario; Adamo, Vincenzo; Colucci; Cognetti, Francesco; De Placido; Masci.

In: Default journal, Vol. x, 2011.

Risultato della ricerca: Article

Gebbia, N, Conte, Ricciardi, GRR, Venturini, Dondi, Giuffrida, D, Adamo, V, Colucci, Cognetti, F, De Placido & Masci 2011, 'Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience.', Default journal, vol. x.
Gebbia, Nicolo' ; Conte ; Ricciardi, Giuseppina Rosaria Rita ; Venturini ; Dondi ; Giuffrida, Dario ; Adamo, Vincenzo ; Colucci ; Cognetti, Francesco ; De Placido ; Masci. / Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience. In: Default journal. 2011 ; Vol. x.
@article{eb50f6564cef45a18b9dd80aae4af86b,
title = "Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience.",
abstract = "AIMS: Triple-negative breast cancers (TNBCs) lack expression of oestrogen, progesterone, and Human Epidermal Growth Factor 2 receptors. The NEMESI study described current Italian treatment practices in patients with operable, early-stage breast cancer (EBC).PATIENTS AND METHODS: Retrospective, observational study involving 63 Italian oncology centres. Eligible patients were aged ⩾18years with EBC (stage I-II) who had undergone surgery, received ⩾1 cycle of adjuvant chemotherapy and/or adjuvant hormonal therapy and attended an oncology centre between 1 January 2008 and 30 June 2008. This subanalysis focused on patients with TNBC. Variables evaluated included: demographic data/clinical characteristics; tumour characteristics; adjuvant therapy; compliance to chemotherapy. Continuous variables were summarised using descriptive statistics.RESULTS: Of 1894 patients in the NEMESI study, 185 patients (9.8{\%}) had TNBC. At diagnosis, 98 patients were aged 50-70years and 114 were post-menopausal. Tumours were subcategorised as pT1mic/pT1a/pT1b/pT1c in 108 patients and pT2/pT3/pT4b in 77 patients. Mean tumour size was 2.1cm, tumours were highly undifferentiated in 144 patients and 128 patients were pNO. 179 patients received adjuvant chemotherapy; anthracyclines with or without taxanes were commonly used. 145 patients received radiotherapy.CONCLUSIONS: Adherence of Italian clinical practice to International Guidelines in the management of early-stage TNBC is satisfactory.",
keywords = "Adjuvant therapy, Clinical practice, Guidelines, Italy, National register, Triple-negative breast cancer",
author = "Nicolo' Gebbia and Conte and Ricciardi, {Giuseppina Rosaria Rita} and Venturini and Dondi and Dario Giuffrida and Vincenzo Adamo and Colucci and Francesco Cognetti and {De Placido} and Masci",
year = "2011",
language = "English",
volume = "x",
journal = "Default journal",

}

TY - JOUR

T1 - Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience.

AU - Gebbia, Nicolo'

AU - Conte, null

AU - Ricciardi, Giuseppina Rosaria Rita

AU - Venturini, null

AU - Dondi, null

AU - Giuffrida, Dario

AU - Adamo, Vincenzo

AU - Colucci, null

AU - Cognetti, Francesco

AU - De Placido, null

AU - Masci, null

PY - 2011

Y1 - 2011

N2 - AIMS: Triple-negative breast cancers (TNBCs) lack expression of oestrogen, progesterone, and Human Epidermal Growth Factor 2 receptors. The NEMESI study described current Italian treatment practices in patients with operable, early-stage breast cancer (EBC).PATIENTS AND METHODS: Retrospective, observational study involving 63 Italian oncology centres. Eligible patients were aged ⩾18years with EBC (stage I-II) who had undergone surgery, received ⩾1 cycle of adjuvant chemotherapy and/or adjuvant hormonal therapy and attended an oncology centre between 1 January 2008 and 30 June 2008. This subanalysis focused on patients with TNBC. Variables evaluated included: demographic data/clinical characteristics; tumour characteristics; adjuvant therapy; compliance to chemotherapy. Continuous variables were summarised using descriptive statistics.RESULTS: Of 1894 patients in the NEMESI study, 185 patients (9.8%) had TNBC. At diagnosis, 98 patients were aged 50-70years and 114 were post-menopausal. Tumours were subcategorised as pT1mic/pT1a/pT1b/pT1c in 108 patients and pT2/pT3/pT4b in 77 patients. Mean tumour size was 2.1cm, tumours were highly undifferentiated in 144 patients and 128 patients were pNO. 179 patients received adjuvant chemotherapy; anthracyclines with or without taxanes were commonly used. 145 patients received radiotherapy.CONCLUSIONS: Adherence of Italian clinical practice to International Guidelines in the management of early-stage TNBC is satisfactory.

AB - AIMS: Triple-negative breast cancers (TNBCs) lack expression of oestrogen, progesterone, and Human Epidermal Growth Factor 2 receptors. The NEMESI study described current Italian treatment practices in patients with operable, early-stage breast cancer (EBC).PATIENTS AND METHODS: Retrospective, observational study involving 63 Italian oncology centres. Eligible patients were aged ⩾18years with EBC (stage I-II) who had undergone surgery, received ⩾1 cycle of adjuvant chemotherapy and/or adjuvant hormonal therapy and attended an oncology centre between 1 January 2008 and 30 June 2008. This subanalysis focused on patients with TNBC. Variables evaluated included: demographic data/clinical characteristics; tumour characteristics; adjuvant therapy; compliance to chemotherapy. Continuous variables were summarised using descriptive statistics.RESULTS: Of 1894 patients in the NEMESI study, 185 patients (9.8%) had TNBC. At diagnosis, 98 patients were aged 50-70years and 114 were post-menopausal. Tumours were subcategorised as pT1mic/pT1a/pT1b/pT1c in 108 patients and pT2/pT3/pT4b in 77 patients. Mean tumour size was 2.1cm, tumours were highly undifferentiated in 144 patients and 128 patients were pNO. 179 patients received adjuvant chemotherapy; anthracyclines with or without taxanes were commonly used. 145 patients received radiotherapy.CONCLUSIONS: Adherence of Italian clinical practice to International Guidelines in the management of early-stage TNBC is satisfactory.

KW - Adjuvant therapy

KW - Clinical practice

KW - Guidelines

KW - Italy

KW - National register

KW - Triple-negative breast cancer

UR - http://hdl.handle.net/10447/59205

M3 - Article

VL - x

JO - Default journal

JF - Default journal

ER -